As per recent outcomes of a study published in Cephalalgia, erenumab preserves cerebral vasomotor reactivity and FMD in migraine patients without aura.

Claudia Altamura and investigators examined if erenumab affects the cerebral vasomotor reactivity and FMD in migraine.

This observational longitudinal study comprised of migraineurs who were prescribed erenumab. Participants underwent assessment for brachial corrected FMD at baseline i.e. T0 and for cerebral vasomotor reactivity to hypercapnia (breath-holding index) in the mid and posterior cerebral arteries.

This examination was done following two weeks from the first erenumab injection i.e. T2 and following two weeks from the fourth Erenumab injection i.e. T18. Thereafter, the responders were described as the patients exhibiting a decrease of at least 50% in monthly migraine days following completing the fourth month of the treatment.

Overall, 60 patients and 25 controls participated in this study. In both patients and controls, no variation was witnessed in the middle and posterior cerebral artery mean flow velocities, breath-holding index, and FMD at T0 and T0-T2.

In patients having migraine, no alteration in the explored variables from T0 to T18 nor a link between examination times (T0-T2 or T0-T18) and chronic conditions at T0, the fourth dose of erenumab or responder state were witnessed.

The study findings revealed that erenumab does not modify brachial FMD and cerebral vasomotor reactivity. Individuals having episodic and chronic migraine and control subjects present comparable cerebral vasomotor reactivity and brachial FMD. Cerebral vasomotor reactivity and brachial FMD cannot be utilized to predict erenumab effectiveness.

Thus, in migraineurs without aura, erenumab preserves cerebral vasomotor reactivity and FMD.